Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

OBJECTIVES: The interleukin-6 receptor (IL-6R) blocker tocilizumab (TCZ) reduces inflammatory disease activity in rheumatoid arthritis (RA) but elevates lipid concentrations in some patients. We aimed to characterise the impact of IL-6R inhibition on established and novel risk factors in active RA....

Descripción completa

Detalles Bibliográficos
Autores principales: McInnes, Iain B, Thompson, Liz, Giles, Jon T, Bathon, Joan M, Salmon, Jane E, Beaulieu, Andre D, Codding, Christine E, Carlson, Timothy H, Delles, Christian, Lee, Janet S, Sattar, Naveed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392313/
https://www.ncbi.nlm.nih.gov/pubmed/24368514
http://dx.doi.org/10.1136/annrheumdis-2013-204345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392313/
https://www.ncbi.nlm.nih.gov/pubmed/24368514
http://dx.doi.org/10.1136/annrheumdis-2013-204345

Ejemplares similares